Taihe Hospital
十堰市太和医院
Listed for 8 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
No official website checked for this hospital yet.
Research at Taihe Hospital
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Oesophageal squamous cell carcinoma食管鳞状细胞癌6 papers led
- Hepatocellular carcinoma肝细胞癌16 papers led
- Osteosarcoma骨肉瘤0 papers led
- Myasthenia gravis重症肌无力2 papers led
- Amyotrophic lateral sclerosis肌萎缩侧索硬化症0 papers led
- Behçet disease白塞病0 papers led
- Primary biliary cholangitis原发性胆汁性胆管炎0 papers led
- Leber hereditary optic neuropathyLeber 遗传性视神经病变3 papers led
Not listed for: Nasopharyngeal carcinoma, Stomach cancer, Hepatoblastoma, Retinoblastoma, Chordoma, Gastrointestinal stromal tumour, Neuroblastoma, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Oesophageal squamous cell carcinoma
食管鳞状细胞癌Led 6 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Shiyan for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma
No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Hospital name read automatically from author addresses, not yet checked by hand.
Papers it led6
- Pristimerin induces Noxa-dependent apoptosis by activating the FoxO3a pathway in esophageal squamous cell carcinoma.
- Overexpression of ATP1B2 promotes cancer cell migration and inhibits apoptosis in patients with esophageal squamous cell carcinoma.
- TET2 Is Downregulated in Early Esophageal Squamous Cell Carcinoma and Promotes Esophageal Squamous Cell Malignant Behaviors.
- Inhibiting the expression of spindle appendix cooled coil protein 1 can suppress tumor cell growth and metastasis and is associated with cancer immune cells in esophageal squamous cell carcinoma.
- Inhibition of p62 and/or NFE2L2 induced autophagy impaires esophageal squamous cell cancer metastasis by reversing EMT.
- Esophageal Squamous Cell Carcinoma: Time to Predict the Risk?
Chinese-language papers (not in the count)1
More papers found outside PubMed (not counted)1
Cancer
Hepatocellular carcinoma
肝细胞癌Led 16 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Shiyan for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma
No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Hospital name read automatically from author addresses, not yet checked by hand.
Papers it led16
- SGLT2i delays c-Myc-induced HCC progression via targeting mTOR.
- Levels of Bile Acid Metabolism Are Associated With Alterations of Gut Microbes in Hepatocellular Carcinoma.
- Correlation analysis of mitochondrial DNA maintenance-related genes with HCC prognosis, tumor mutation burden and tumor microenvironment features.
- A real-world drug safety surveillance study from the FAERS database of hepatocellular carcinoma patients receiving pembrolizumab alone and plus lenvatinib.
- The delaying effect of toripalimab on disease progression in patients with advanced hepatocellular carcinoma and changes in serum tumor markers.
- The role and mechanism of HIF-1α-mediated glypican-3 secretion in hypoxia-induced tumor progression in hepatocellular carcinoma.
- LncRNA XXYLT1-AS2 promotes tumor progression via autophagy inhibition through ubiquitinated degradation of TFEB in hepatocellular carcinoma.
- Resveratrol Inhibits Hepatocellular Carcinoma Progression through Regulating Exosome Secretion.
- Downregulation of C1R promotes hepatocellular carcinoma development by activating HIF-1α-regulated glycolysis.
- A spliceosome-associated gene signature aids in predicting prognosis and tumor microenvironment of hepatocellular carcinoma.
- Bioinformatics analysis and experimental validation of a novel autophagy-related signature relevant to immune infiltration for recurrence prediction after curative hepatectomy.
- SNRPD1 inhibition suppresses the proliferation of hepatocellular carcinoma and promotes autophagy through the PI3K/AKT/mTOR/4EBP1 pathway.
- Overexpression of SH2D1A promotes cancer progression and is associated with immune cell infiltration in hepatocellular carcinoma via bioinformatics and in vitro study.
- MHBSt167 induced autophagy promote cell proliferation and EMT by activating the immune response in L02 cells.
- Upregulated expression of MTFR2 as a novel biomarker predicts poor prognosis in hepatocellular carcinoma by bioinformatics analysis.
- Rutin attenuates Sorafenib-induced Chemoresistance and Autophagy in Hepatocellular Carcinoma by regulating BANCR/miRNA-590-5P/OLR1 Axis.
Cancer
Osteosarcoma
骨肉瘤Led no English-language PubMed papers on osteosarcoma in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Shiyan for osteosarcoma570 hospitals in China for osteosarcoma
No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Earlier papers (2016–2020)3
- Effects of PAK4/LIMK1/Cofilin-1 signaling pathway on proliferation, invasion, and migration of human osteosarcoma cells.
- Expression of the Nrf2 and Keap1 proteins and their clinical significance in osteosarcoma.
- Vascular endothelial growth factor polymorphisms are associated with osteosarcoma susceptibility.
Other diseases
Myasthenia gravis
重症肌无力Led 2 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Shiyan for myasthenia gravis89 hospitals in China for myasthenia gravis
No open trial on myasthenia gravis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Other diseases
Amyotrophic lateral sclerosis
肌萎缩侧索硬化症Led no English-language PubMed papers on amyotrophic lateral sclerosis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Shiyan for amyotrophic lateral sclerosis182 hospitals in China for amyotrophic lateral sclerosis
No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Other diseases
Behçet disease
白塞病Led no English-language PubMed papers on Behçet disease in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Shiyan for Behçet disease139 hospitals in China for Behçet disease
No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Other diseases
Primary biliary cholangitis
原发性胆汁性胆管炎Led no English-language PubMed papers on primary biliary cholangitis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
1 hospital in Shiyan for primary biliary cholangitis153 hospitals in China for primary biliary cholangitis
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
- Phase
- Phase 3
- Started
- 2025-12
- Registry
- NCT07282353
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBaoji, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou, Harbin, Hefei, Linyi, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shiyan, Taizhou, Tianjin, Xi'an, Xiamen, Zhanjiang, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
All its trials on ClinicalTrials.gov, any status1
Other diseases
Leber hereditary optic neuropathy
Leber 遗传性视神经病变Led 3 of the 52 English-language PubMed papers on Leber hereditary optic neuropathy with an author in mainland China, 2021–2025: 5.8%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Shiyan for Leber hereditary optic neuropathy30 hospitals in China for Leber hereditary optic neuropathy
No open trial on Leber hereditary optic neuropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Papers it led3
Earlier papers (2016–2020)3
Other linked evidence
Getting in touch
Name card to show staff or a driver
十堰市太和医院
Taihe Hospital
十堰
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
ROR
Yunyang Region People's Hospital